Impact of nirsevimab implementation on the mid-term burden of bronchiolitis in the outpatient setting: results from the prospective OURSYN study
Clicks: 1
ID: 314037
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #33 of 40 articles by views in journal of the pediatric infectious diseases society
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Context Nirsevimab was implemented in Europe and the US in September 2023. While its effectiveness in preventing RSV-bronchiolitis has been demonstrated by real-life studies, its impact on mid-term child health, quality of life, and parental absenteeism remains unstudied. Methods Infants under 1-year with a first bronchiolitis episode were recruited through the OURSYN study involving 37 primary care pediatricians in France between 2021 and 2025 (pre-nirsevimab period: 02/2021-03/2023 and nirsevimab period: 09/2023-03/2025). RSV status was determined by antigenic nasopharyngeal testing. At day-15, parents reported symptoms, quality of life (PedsQL Infant), and work absenteeism. Their associations with (i) RSV status, (ii) period of inclusion, and (iii) nirsevimab immunization status among RSV-positive cases were assessed using multivariable logistic regression adjusted for confounders. Results Among 1870 bronchiolitis cases included, 637 (34.0%) occurred during the nirsevimab period and 812 (43.4%) were RSV-related. Over the study period, at day-15, RSV-cases had more feeding difficulties (aOR = 1.41 [1.06–1.88]), longer daycare absence (4.7 vs 3.2 days), and more parental absenteeism (aOR = 1.61 [0.99–2.62]) compared to RSV-negative. The proportion of RSV-cases decreased during the nirsevimab period compared with the pre-nirsevimab period (47.1% vs 35.7% p < 0.001). Bronchiolitis cases recruited during this period had shorter daycare absences (3.2 vs 4.3 days). Among RSV-cases, immunized infants had lower risk of persistent fever (aOR = 0.14 [0.01–0.79]). Conclusion This large prospective study provides the first evidence that the mid-term burden of RSV-bronchiolitis in infants may be reduced following the implementation of nirsevimab, with potential benefits for infant health, quality of life and parental absenteeism.
| Reference Key |
openalex_W7161576410
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Léa Lenglart, C Levy, Fabienne Cahn-Sellem, Morched Zouari, Hassid Frederic, Stéphane Béchet, Maeva Boulhol, Rolf Kramer, Alexis Rybak, Naïm Ouldali, Robert Cohen |
| Journal | journal of the pediatric infectious diseases society |
| Year | 2026 |
| DOI |
10.1093/jpids/piag035
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.